Phase 2 N=30 Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Fasting Serum C4 Levels — 2.2; 50.4 ng/ML
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,579 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Stomach Neoplasms
Primary: Overall Survival (OS) in All Participants — 12.9; 11.5 Months — p=<0.0001
N/A N=63 Evaluating a Digital Peer Mentoring Platform With College Student Populations
Well-Being, Psychological · Anxiety · Depression
Primary: Self-reported Depression Symptoms — 8.21; 3.88 score on a scale — p=.182
N/A N=40 A Trial to Test an Acceptance-based Therapy Program Among Adolescent Girls With Overweight/Obesity
Weight Loss · Obesity · Overweight
Primary: BMI Change, 95th BMI Percentile (%) — -1.11; -0.08 Change in the 95th BMI percentile %
Phase 3 N=617 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Cervical Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants With Programmed…
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=20 Poor Sleep and Inflammation in HIV-Infected Adults
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
Phase 2 N=10 Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
Sickle Cell Disease
Primary: Event-free Survival (EFS) Rate — 5 Participants
N/A N=70 Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Sarcoma · Thoracic Cancer · Abdominal Cancer
Primary: Rate of Local Control — 29 Participants
Phase 2 N=120 Blood Pressure After Endovascular Stroke Therapy-II
Acute Stroke · Endovascular Thrombectomy
Primary: Final Infarct Volume — 46.4; 50.7; 32.4 Cubic Centimeters
N/A N=50 A User Study of the Soniflow System for Nasal Congestion Relief
Nasal Congestion
Primary: Total Nasal Symptom Score — 2.0 score on a scale
Phase 2 N=91 Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Number of Participants With Adverse Events — 20; 16; 19; 16 Participants
N/A N=42 Clinical Evaluation of Two Toric Contact Lenses
Astigmatism
Primary: Subjective Handling Ratings on Insertion — 92.0; 93.7 units on a scale
Phase 2 N=3 A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Duchenne Muscular Dystrophy
Primary: Change in Dystrophin Expression From Baseline Following Treatment With Either AMONDYS 45 (Previously Casimersen), EXONDYS 51 (Previously Eteplirsen ), or VYONDYS 53…
N/A N=98 Clinical Comparison of Vital Pulp Capping Restorative Protocols
Deep Dental Caries
Primary: Success Rate Based on Pulp Vitality Tests (Vital/Non Vital) — 96.2; 100; 100; 86 Percentage of success rate — p=>0.1